237 related articles for article (PubMed ID: 20425085)
1. Glucocorticoid-induced osteoporosis: management update.
Adler RA
Curr Osteoporos Rep; 2010 Mar; 8(1):10-4. PubMed ID: 20425085
[TBL] [Abstract][Full Text] [Related]
2. [Mechanisms and therapeutics of glucocorticoid-induced osteoporosis].
Kaneko K; Kawai S
Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(3):138-48. PubMed ID: 21720102
[TBL] [Abstract][Full Text] [Related]
3. Data from extension trials: denosumab and zoledronic acid.
Dore RK
Curr Osteoporos Rep; 2012 Mar; 10(1):16-21. PubMed ID: 22086442
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for glucocorticoid-induced osteoporosis.
Chiodini I; Merlotti D; Falchetti A; Gennari L
Expert Opin Pharmacother; 2020 Apr; 21(6):721-732. PubMed ID: 32004105
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer bone metastases: denosumab or zoledronic acid?
van der Pluijm G
Nat Rev Endocrinol; 2011 Mar; 7(3):134-5. PubMed ID: 21343953
[No Abstract] [Full Text] [Related]
6. Glucocorticoid-induced osteoporosis and osteonecrosis.
Weinstein RS
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):595-611. PubMed ID: 22877431
[TBL] [Abstract][Full Text] [Related]
7. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
Gallacher SJ; Dixon T
Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
[TBL] [Abstract][Full Text] [Related]
8. [Secondary osteoporosis UPDATE. Clinical significance of glucocorticoid-induced osteoporosis].
Suzuki Y; Sato S
Clin Calcium; 2010 May; 20(5):645-53. PubMed ID: 20445275
[TBL] [Abstract][Full Text] [Related]
9. Patient preference, efficacy, and compliance with zoledronic acid for glucocorticoid-induced osteoporosis in patients with autoimmune diseases.
Kim JW; Jung JY; Kim HA; Son H; Suh CH
Postgrad Med J; 2024 Apr; 100(1183):334-341. PubMed ID: 38297995
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
11. Management of glucocorticoid-induced osteoporosis.
Rizzoli R; Adachi JD; Cooper C; Dere W; Devogelaer JP; Diez-Perez A; Kanis JA; Laslop A; Mitlak B; Papapoulos S; Ralston S; Reiter S; Werhya G; Reginster JY
Calcif Tissue Int; 2012 Oct; 91(4):225-43. PubMed ID: 22878667
[TBL] [Abstract][Full Text] [Related]
12. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
[TBL] [Abstract][Full Text] [Related]
13. New therapies for osteoporosis: zoledronic acid, bazedoxifene, and denosumab.
Silverman SL
Curr Osteoporos Rep; 2009 Sep; 7(3):91-5. PubMed ID: 19723467
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials.
Dong B; Zhou Y; Wang J; Li C; Fu Z; Huang Y; Wang Y; Xu L
Horm Metab Res; 2023 Apr; 55(4):236-244. PubMed ID: 36652960
[TBL] [Abstract][Full Text] [Related]
15. Combined effect of teriparatide and an anti-RANKL monoclonal antibody on bone defect regeneration in mice with glucocorticoid-induced osteoporosis.
Etani Y; Ebina K; Hirao M; Kitaguchi K; Kashii M; Ishimoto T; Nakano T; Okamura G; Miyama A; Takami K; Goshima A; Kanamoto T; Nakata K; Yoshikawa H
Bone; 2020 Oct; 139():115525. PubMed ID: 32645445
[TBL] [Abstract][Full Text] [Related]
16. Longer-lasting osteoporosis drugs sought.
Kuehn BM
JAMA; 2005 May; 293(20):2458. PubMed ID: 15914731
[No Abstract] [Full Text] [Related]
17. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
[TBL] [Abstract][Full Text] [Related]
18. What is new in the treatment of steroid-induced osteoporosis?
Liu RH; Werth VP
Semin Cutan Med Surg; 2007 Dec; 26(4):203-9. PubMed ID: 18395668
[TBL] [Abstract][Full Text] [Related]
19. The pharmacological management of osteoporosis.
Riek AE; Towler DA
Mo Med; 2011; 108(2):118-23. PubMed ID: 21568234
[TBL] [Abstract][Full Text] [Related]
20. [Drug-induced osteoporosis].
Tanaka Y
Nihon Rinsho; 2007 Oct; 65 Suppl 8():394-8. PubMed ID: 18074570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
